Somatostatin receptor scintigraphy with <sup>68</sup>Ga-DOTATATE PET/CT: initial experience in Cuba
Main Article Content
Abstract
In 1870, Rudolf Heidenhain discovered neuroendocrine cells, which can lead to the development of the Neuroendocrine Tumors (NER), a rare form of cancer, most of which express somatostatin receptors. The basis of Receptor Scintigraphy as a metabolic-molecular image is based on the use of 68Ga-DOTA-peptides with specific binding to somatostatin receptors.The purpose of this publication is to present our first experiences in the study of different histological types of TNE by means of Somatostatin Receptor Scintigraphy (GRS) using 68Ga-DOTATATE performed at the PET / CT Center and Molecular Image of the Department of Nuclear Medicine of the National Institute of Oncology and Radiobiology (Inor).
Article Details
How to Cite
Oliva González, J. P. (1). Somatostatin receptor scintigraphy with <sup>68</sup>Ga-DOTATATE PET/CT: initial experience in Cuba. Nucleus, (62), 14-23. Retrieved from http://nucleus.cubaenergia.cu/index.php/nucleus/article/view/20
Section
Panorama Nuclear
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. Bajo esta licencia el autor será libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y crear a partir del material
- El licenciador no puede revocar estas libertades mientras cumpla con los términos de la licencia
Bajo las siguientes condiciones:
- Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
- NoComercial — No puede utilizar el material para una finalidad comercial.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
La Revista Nucleus solo aceptará contribuciones que no hayan sido previamente publicados y/o procesados, por otra publicación. Cualquier violación ese sentido será considerada una falta grave por parte del autor principal lo cual será objeto valoración por parte del Consejo Editorial, el cual dictaminará al respecto.
References
[1]. HEIDENHAIN R. Untersuchungen über den Bau der Labdrüsen. Arch für Mikrosk Anat. 1870; 6: 368-406.
[2]. BAUM RP, PURANIK, A KULKARNI HR. Peptide receptor radionuclide therapy(PRRT) of neuroendocrine tumors: current state and future perspectives. Int. J. End. Oncol. 2015; 2(2): 151-158.
[3]. MODLIN IM, OBERG K, CHUNG DC. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008; 9(1): 61-72.
[4]. MODLIN IM, LYE KD, KIDD M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97(4): 934-959.
[5]. OBERNDORFER S. Karzinoide Handbuch der Speziellen. In: Handbuch der Speziellen Pathologischen Anatomie und Histalagie. Berlin, Germany: Verlag von Julius Springer; 1928. P. 814-817.
[6]. DEPPEN AD, LIU E, BLUME JD, et. al. Safety and efficacy of 68Ga-DOTATATE for diagnosis, staging and treatment management of neuroendocrine tumors. J Nucl Med. 2016; 57(5):708-714.
[7]. BAUM RP, HOFMANN M. Nuklearmedizinische diagnostik neuroendokriner tumoren. Onkologe 2004; 10(6): 598-610.
[8]. EHRLICH P. Croonian lecture: on immunity with special reference to cell life . Proc Royal Soc London. 1900; 66: 424-448.
[9]. BAUM RP, KULKARNI,HR, CARRERAS C. Peptides and receptors in Image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med. 2012; 42(3): 190-207.
[10]. BAUM RP, PRASAD V, HOMMAN, HÖRSCH D. Receptor PET(CT Imaging of Neuroendorine Tumors. Recent Results Cancer Res. 2008; 170: 225-42.
[11]. de HERDER WW, HOFLAND LJ, van der LELY AJ, LAMBERTS SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. EndocrRelat Cancer. 2003;10(4): 451-458.
[12]. MUELLER D, KLETTE I, BAUM RP, et. al. Simplified NaCl based 68Ga concentration and labeling procedure for rapid synthesis of 68Ga radiopharmaceuticals in high radiochemical purity. Bioconjug Chem. 2012; 23(8): 1712-1717.
[13]. SCHULTZ M, MUELLER D, BAUM RP, et. al. A new automated NaCl based robust method for routine production of gallium-68 labeled peptides. Appl Radiat Isot. 2013; 76: 46-54.
[14]. RUFINI V, CALCAGNI L., BAUM RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006; 36(3): 228-247.
[15]. KULKARNI HR, SINGH A, BAUM RP. Advances in the diagnosis of neuroendocrine neoplasms. Semin Nucl Med. 2016; 46(5): 395-404.
[16]. HÖRSCH D, SCHMIDT KW, ANLAUF M, et. al. Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an Expert Meeting February 2011 in Weimar, Germany. Oncol Res Treat. 2014; 37(5): 266-276.
[17]. BODEI L, KWEKKEBOOM DJ, KIDD M, et. al. Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer. Semin Nucl Med. 2016; 46(3): 225-238.
[18]. GRAVEL G, .,GIMENEZ-ROQUEPLO, AP, HALIMI P. 68Ga-DOTATATE PET/CT Versus MRI: Why the Comparison of 68Ga-DOTATATE PET/CT to an Appropriate MRI Protocol Is Essential. J Nucl Med. 2017; 58(1): 184-185.
[19]. DEMIRC. E, AKYEL R., KILIC F, et. al. Dual false positive of 68 Ga-DOTA-TATE PET/CT scan in a patient with a history of pancreatic neuroendocrine tumor: A case report. Rev Esp Med Nucl Imagen Mol. 2015; 34(2): 133-135.
[20]. AGRAWAL K, ESMAIL AA, GNANASEGARAN G, et. al. Pitfalls and Limitations of Radionuclide Imaging in Endocrinology. Semin Nucl Med. 2015; 45(5): 440-457.
[21]. REUBI JC, WASER B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. . Eur J Nucl Med Mol Imaging. 2003; 30(5): 781-793.
[22]. REUBI JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003; 24(4): 389-427.
[23]. MAURICE JB, TROKE R, WIN Z, et. al. A comparison of the performande of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012; 39(8): 1266-1270.
[24]. AMBROSSINI V, CAMPANA D, BODEI L, et. al. 68Ga-DOFTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010; 51(5): 669-773.
[25]. KULAKSIZ H, EISSELE R, ROESSLER D, et. al. Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002; 50(1): 52-60.
[26]. KWEKKEBOOM DJ, KAM BL, van ESSEN M, et. al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010; 17(1): R53-73.
[27]. KAEMMERER D, PETER L, LUPP A, et. al. Molecular imaging with 68Ga-SSTR PET/CT and correlation of immunohistochemistry of somatostatin receptors in neuroendocrine tumour. Eur J Nucl Med Mol Imaging. 2011; 38(9): 1659-1668.
[28]. KABASAKAL L, DEMIRCI E, OCAK, M, et. al. Comparison of 68Ga-DOTATATE and 68GA-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012; 39(8): 1271-1277.
[29]. LAIRMORE TC, WELLS SA Jr. Medullary carcinoma of the thyroid: current diagnosis and management. Semin Surg Oncol.1991; 7(2): 92-99.
[30]. ORLANDINI F, CARACI P, MUSSA A. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer. 2001; 8(2): 135-147.
[31]. ABDELMOUMENE N, SCHLUMBERGER M, GARDET P. Selective venous sampling catheterization for localization of persisting medullary thyroid carcinoma. Br J Cancer.1994; 69(6): 1141-1144.
[32]. KEBEBEW E, ITUARTE PH, SIPERSTEIN AE. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging system. Cancer. 2000; 88(5): 1139-1148.
[33]. SZAVCSUR P, GODENY M, BAJZIK G. Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. Eur J Surg Oncol. 2005; 31(2): 183-190.
[34]. GAZTAMBIDE SD. Diagnóstico y clínica de los carcinoides intestinales. El síndrome carcinoide. Endocrinol Nutr. 2007; 54(Supl 1): 9-14
[35]. ÖBERG KE, REUBI JC, KWEKKEBOOM DJ, KRENNING EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010; 139(3): 742-753.
[36]. SALAZAR R, VILLABONA C, FABREGAT J. Tumores neuroendocrinos gastrointestinales y pancreáticos. Med Clin. 2006; 127(6): 227-231.
[37]. VILLABONA C, CASANOVAS O, SALAZAR R. Biologia molecular, epidemiologia y clasificación de los tumores neurendocrinos gastroenetropancreáticos. Endocrinol Nutr. 2007; 54(Supl 1): 2-8.
[38]. SCIHILLING FH, BIHL H, JACOBSON H. Combined 111In Pentetrotide scintigraphy and 123ImIBG scintigraphy in neuroblastoma provides prognostic information. Med Pediatr Oncol. 2000; 35(6): 688-691.
[39]. KUSHNER BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 2004; 45(7): 1172-1188.
[40]. SÁNCHEZ-GRANJEL M, BENITO F, BATUECAS A. Recuerdo histórico y epidemiología. Acta Otorrinolaringol Esp. 2009; 60 Supl. 1:3-8.
[41]. PÉREZ D, GUTIÉRREZ R, RAMOS A. Clasificación de los paragangliomas cervicocefálicos. Acta Otorrinolaringol Esp. 2009; 60(Supl. 1): 29-33.
[42]. TORRES MORIENTES LM, MENA DOMÍNGUEZ EA, FERNÁNDEZ RODRÍGUEZ A, et. al. Manejo de tres paragangliomas carotídeos y revisión del tema. Rev. Soc. Otorrinolaringol. Castilla Leon Cantab. La Rioja. 2014; 5(9): 75-84.
[43]. MUNDSCHENK J, UNGER N, SCHULZ S, et. al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab. 2003; 88(11): 5150-5157.
[44]. HALPERIN I. Insulinoma. Endocrinol Nutr. 2007; 54(Supl1): 15-20.
[45]. OLIVA JP & BAUM RP. Dual tracer/dual isotope 68Ga-DOTANOC and 18F-FDG PET/CT: A one day protocol in a child with neuroblastoma for determining the receptor status and the metabolic tumor state. First World Congress of 68Ga-Somatostatine. Bad Berka. Turingia. Alemania. 2014.
[2]. BAUM RP, PURANIK, A KULKARNI HR. Peptide receptor radionuclide therapy(PRRT) of neuroendocrine tumors: current state and future perspectives. Int. J. End. Oncol. 2015; 2(2): 151-158.
[3]. MODLIN IM, OBERG K, CHUNG DC. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008; 9(1): 61-72.
[4]. MODLIN IM, LYE KD, KIDD M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97(4): 934-959.
[5]. OBERNDORFER S. Karzinoide Handbuch der Speziellen. In: Handbuch der Speziellen Pathologischen Anatomie und Histalagie. Berlin, Germany: Verlag von Julius Springer; 1928. P. 814-817.
[6]. DEPPEN AD, LIU E, BLUME JD, et. al. Safety and efficacy of 68Ga-DOTATATE for diagnosis, staging and treatment management of neuroendocrine tumors. J Nucl Med. 2016; 57(5):708-714.
[7]. BAUM RP, HOFMANN M. Nuklearmedizinische diagnostik neuroendokriner tumoren. Onkologe 2004; 10(6): 598-610.
[8]. EHRLICH P. Croonian lecture: on immunity with special reference to cell life . Proc Royal Soc London. 1900; 66: 424-448.
[9]. BAUM RP, KULKARNI,HR, CARRERAS C. Peptides and receptors in Image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med. 2012; 42(3): 190-207.
[10]. BAUM RP, PRASAD V, HOMMAN, HÖRSCH D. Receptor PET(CT Imaging of Neuroendorine Tumors. Recent Results Cancer Res. 2008; 170: 225-42.
[11]. de HERDER WW, HOFLAND LJ, van der LELY AJ, LAMBERTS SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. EndocrRelat Cancer. 2003;10(4): 451-458.
[12]. MUELLER D, KLETTE I, BAUM RP, et. al. Simplified NaCl based 68Ga concentration and labeling procedure for rapid synthesis of 68Ga radiopharmaceuticals in high radiochemical purity. Bioconjug Chem. 2012; 23(8): 1712-1717.
[13]. SCHULTZ M, MUELLER D, BAUM RP, et. al. A new automated NaCl based robust method for routine production of gallium-68 labeled peptides. Appl Radiat Isot. 2013; 76: 46-54.
[14]. RUFINI V, CALCAGNI L., BAUM RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006; 36(3): 228-247.
[15]. KULKARNI HR, SINGH A, BAUM RP. Advances in the diagnosis of neuroendocrine neoplasms. Semin Nucl Med. 2016; 46(5): 395-404.
[16]. HÖRSCH D, SCHMIDT KW, ANLAUF M, et. al. Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an Expert Meeting February 2011 in Weimar, Germany. Oncol Res Treat. 2014; 37(5): 266-276.
[17]. BODEI L, KWEKKEBOOM DJ, KIDD M, et. al. Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer. Semin Nucl Med. 2016; 46(3): 225-238.
[18]. GRAVEL G, .,GIMENEZ-ROQUEPLO, AP, HALIMI P. 68Ga-DOTATATE PET/CT Versus MRI: Why the Comparison of 68Ga-DOTATATE PET/CT to an Appropriate MRI Protocol Is Essential. J Nucl Med. 2017; 58(1): 184-185.
[19]. DEMIRC. E, AKYEL R., KILIC F, et. al. Dual false positive of 68 Ga-DOTA-TATE PET/CT scan in a patient with a history of pancreatic neuroendocrine tumor: A case report. Rev Esp Med Nucl Imagen Mol. 2015; 34(2): 133-135.
[20]. AGRAWAL K, ESMAIL AA, GNANASEGARAN G, et. al. Pitfalls and Limitations of Radionuclide Imaging in Endocrinology. Semin Nucl Med. 2015; 45(5): 440-457.
[21]. REUBI JC, WASER B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. . Eur J Nucl Med Mol Imaging. 2003; 30(5): 781-793.
[22]. REUBI JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003; 24(4): 389-427.
[23]. MAURICE JB, TROKE R, WIN Z, et. al. A comparison of the performande of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012; 39(8): 1266-1270.
[24]. AMBROSSINI V, CAMPANA D, BODEI L, et. al. 68Ga-DOFTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010; 51(5): 669-773.
[25]. KULAKSIZ H, EISSELE R, ROESSLER D, et. al. Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002; 50(1): 52-60.
[26]. KWEKKEBOOM DJ, KAM BL, van ESSEN M, et. al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010; 17(1): R53-73.
[27]. KAEMMERER D, PETER L, LUPP A, et. al. Molecular imaging with 68Ga-SSTR PET/CT and correlation of immunohistochemistry of somatostatin receptors in neuroendocrine tumour. Eur J Nucl Med Mol Imaging. 2011; 38(9): 1659-1668.
[28]. KABASAKAL L, DEMIRCI E, OCAK, M, et. al. Comparison of 68Ga-DOTATATE and 68GA-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012; 39(8): 1271-1277.
[29]. LAIRMORE TC, WELLS SA Jr. Medullary carcinoma of the thyroid: current diagnosis and management. Semin Surg Oncol.1991; 7(2): 92-99.
[30]. ORLANDINI F, CARACI P, MUSSA A. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer. 2001; 8(2): 135-147.
[31]. ABDELMOUMENE N, SCHLUMBERGER M, GARDET P. Selective venous sampling catheterization for localization of persisting medullary thyroid carcinoma. Br J Cancer.1994; 69(6): 1141-1144.
[32]. KEBEBEW E, ITUARTE PH, SIPERSTEIN AE. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging system. Cancer. 2000; 88(5): 1139-1148.
[33]. SZAVCSUR P, GODENY M, BAJZIK G. Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. Eur J Surg Oncol. 2005; 31(2): 183-190.
[34]. GAZTAMBIDE SD. Diagnóstico y clínica de los carcinoides intestinales. El síndrome carcinoide. Endocrinol Nutr. 2007; 54(Supl 1): 9-14
[35]. ÖBERG KE, REUBI JC, KWEKKEBOOM DJ, KRENNING EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010; 139(3): 742-753.
[36]. SALAZAR R, VILLABONA C, FABREGAT J. Tumores neuroendocrinos gastrointestinales y pancreáticos. Med Clin. 2006; 127(6): 227-231.
[37]. VILLABONA C, CASANOVAS O, SALAZAR R. Biologia molecular, epidemiologia y clasificación de los tumores neurendocrinos gastroenetropancreáticos. Endocrinol Nutr. 2007; 54(Supl 1): 2-8.
[38]. SCIHILLING FH, BIHL H, JACOBSON H. Combined 111In Pentetrotide scintigraphy and 123ImIBG scintigraphy in neuroblastoma provides prognostic information. Med Pediatr Oncol. 2000; 35(6): 688-691.
[39]. KUSHNER BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 2004; 45(7): 1172-1188.
[40]. SÁNCHEZ-GRANJEL M, BENITO F, BATUECAS A. Recuerdo histórico y epidemiología. Acta Otorrinolaringol Esp. 2009; 60 Supl. 1:3-8.
[41]. PÉREZ D, GUTIÉRREZ R, RAMOS A. Clasificación de los paragangliomas cervicocefálicos. Acta Otorrinolaringol Esp. 2009; 60(Supl. 1): 29-33.
[42]. TORRES MORIENTES LM, MENA DOMÍNGUEZ EA, FERNÁNDEZ RODRÍGUEZ A, et. al. Manejo de tres paragangliomas carotídeos y revisión del tema. Rev. Soc. Otorrinolaringol. Castilla Leon Cantab. La Rioja. 2014; 5(9): 75-84.
[43]. MUNDSCHENK J, UNGER N, SCHULZ S, et. al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab. 2003; 88(11): 5150-5157.
[44]. HALPERIN I. Insulinoma. Endocrinol Nutr. 2007; 54(Supl1): 15-20.
[45]. OLIVA JP & BAUM RP. Dual tracer/dual isotope 68Ga-DOTANOC and 18F-FDG PET/CT: A one day protocol in a child with neuroblastoma for determining the receptor status and the metabolic tumor state. First World Congress of 68Ga-Somatostatine. Bad Berka. Turingia. Alemania. 2014.